702 related articles for article (PubMed ID: 25523285)
1. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
[TBL] [Abstract][Full Text] [Related]
2. Memantine for dementia.
McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
Fox C; Crugel M; Maidment I; Auestad BH; Coulton S; Treloar A; Ballard C; Boustani M; Katona C; Livingston G
PLoS One; 2012; 7(5):e35185. PubMed ID: 22567095
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Herrmann N; Gauthier S; Boneva N; Lemming OM;
Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
[TBL] [Abstract][Full Text] [Related]
5. Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine Comparative Trial study).
Yoon SJ; Choi SH; Na HR; Park KW; Kim EJ; Han HJ; Lee JH; Shim YS; Na DL
Geriatr Gerontol Int; 2017 Mar; 17(3):494-499. PubMed ID: 27111084
[TBL] [Abstract][Full Text] [Related]
6. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
8. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings JL; Schneider E; Tariot PN; Graham SM;
Neurology; 2006 Jul; 67(1):57-63. PubMed ID: 16832078
[TBL] [Abstract][Full Text] [Related]
9. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Wilcock GK; Ballard CG; Cooper JA; Loft H
J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
11. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
Gauthier S; Wirth Y; Möbius HJ
Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
[TBL] [Abstract][Full Text] [Related]
12. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
Ballard C; Hanney ML; Theodoulou M; Douglas S; McShane R; Kossakowski K; Gill R; Juszczak E; Yu LM; Jacoby R;
Lancet Neurol; 2009 Feb; 8(2):151-7. PubMed ID: 19138567
[TBL] [Abstract][Full Text] [Related]
13. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
[TBL] [Abstract][Full Text] [Related]
14. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
15. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
[TBL] [Abstract][Full Text] [Related]
16. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial.
Ballard C; Corbett A; Orrell M; Williams G; Moniz-Cook E; Romeo R; Woods B; Garrod L; Testad I; Woodward-Carlton B; Wenborn J; Knapp M; Fossey J
PLoS Med; 2018 Feb; 15(2):e1002500. PubMed ID: 29408901
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
Zhang N; Wei C; Du H; Shi FD; Cheng Y
Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
[TBL] [Abstract][Full Text] [Related]
18. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
19. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
